On November 11, Novanta rose 5.16% in Regular Trading, trading at $129.81, with turnover of $39.08 million.
The move followed the company’s latest quarterly report, which exceeded market expectations, while investors also focused on contributions from the recently acquired Riverpoint Medical business.
For the quarter ended in early October, Novanta reported adjusted EPS of $1.05 on revenue of $305.0 million, above consensus estimates of $0.97 and $301.0 million, respectively. Revenue increased 23% year over year, with about $32.9 million of contribution tied to Riverpoint Medical consolidation.
Management guided fourth-quarter adjusted EPS to $0.91 to $0.96 on revenue of $306 million to $312 million, while full-year adjusted EPS was set at $3.66 to $3.71 on revenue of $1.135 billion to $1.140 billion. Riverpoint had been presented earlier as immediately accretive to growth, margins, earnings, and cash flow, reinforcing the market’s focus on acquisition synergy.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments